The Mutant Form of Lamin A that Causes Hutchinson-Gilford Progeria Is a Biomarker of Cellular Aging in Human Skin by McClintock, Dayle et al.
The Mutant Form of Lamin A that Causes Hutchinson-





1, David M. Owens
1,2, Leslie B. Gordon
3, Francis S. Collins
4, Karima Djabali
1*
1Department of Dermatology, College of Physicians and Surgeons, Columbia University, New York, New York, United States of America,
2Department of Pathology, College of Physicians and Surgeons, Columbia University, New York, New York, United States of America, 3Department of
BioMed Pediatrics, Brown University, Providence, Rhode Island, United States of America, 4Genome Technology Branch, National Human Genome
Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America
Hutchinson-Gilford progeria syndrome (HGPS, OMIM 176670) is a rare disorder characterized by accelerated aging and early
death, frequently from stroke or coronary artery disease. 90% of HGPS cases carry the LMNA G608G (GGC.GGT) mutation
within exon 11 of LMNA, activating a splice donor site that results in production of a dominant negative form of lamin A
protein, denoted progerin. Screening 150 skin biopsies from unaffected individuals (newborn to 97 years) showed that a similar
splicing event occurs in vivo at a low level in the skin at all ages. While progerin mRNA remains low, the protein accumulates in
the skin with age in a subset of dermal fibroblasts and in a few terminally differentiated keratinocytes. Progerin-positive
fibroblasts localize near the basement membrane and in the papillary dermis of young adult skin; however, their numbers
increase and their distribution reaches the deep reticular dermis in elderly skin. Our findings demonstrate that progerin
expression is a biomarker of normal cellular aging and may potentially be linked to terminal differentiation and senescence in
elderly individuals.
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INTRODUCTION
Lamins of the A- and B-type are intermediate filament proteins
that constitute major components of the nuclear lamina,
a filamentous meshwork forming an interface between the inner
nuclear membrane and the chromatin [1]. Lamins A and C, the
major isoforms of A-type lamins, are expressed in all differentiated
vertebrate cells [2] and are translated from alternatively spliced
transcripts of the LMNA gene. In contrast to the single LMNA
gene, there are two B-type lamin genes: LMNB1 gene encodes
lamin B1 protein [3,4], while LMNB2 encodes two protein
products by alternative splicing: lamin B2 and lamin B3, [5,6].
The B-type lamins are expressed throughout development, and
one or more B-type lamins are present in all cell types [7–9]
Lamins are located at the nuclear lamina and throughout the
nucleoplasm [10,11], where they seem to play fundamental roles
in the shape, integrity and function of the nucleus and in DNA
replication and RNA transcription [12]. Lamin A and lamin B are
modified at their carboxyl-terminal –CAAX box through a series
of post-translational modifications. The modifications include,
successively, farnesylation of the cysteine in the C-terminal CaaX
motif (C, cysteine; a, aliphatic; X, any amino acid), followed by
a proteolytic cleavage of the aaX-terminal tripeptide, and by
methylation of the farnesylated cysteine [13]. While B-type lamins
remain permanently farnesylated, prelamin A (the precursor of
mature lamin A) undergoes a second cleavage of the remaining 15
C-terminal residues (aa 647–661) to give rise to the mature lamin
A, therefore losing its farnesyl modification [13,14]. The enzyme
responsible for these sequential proteolytic cleavages is the zinc
metalloproteinase ZMSPTE24, for which lamin A is the only
known substrate in mammals [15].
Mutations in LMNA are implicated in 12 distinct disorders,
commonly referred to as laminopathies, and involve different tissues,
including muscle, peripheral nerve, adipose, bone and skin tissue.
These disorders exhibit distinct clinical phenotypes associated with
features such as myopathy, cardiomyopathy, lipodystrophy, neurop-
athyandpremature aging[16–18].Thetwo best-known examplesof
accelerated aging syndrome in humans are Hutchinson-Gilford
progeria syndrome (HGPS, ‘Progeria of childhood’) and Werner
syndrome (WS, ‘Progeria of the adult’). Whereas most cases of WS
have been caused by mutations in WRN helicase [19], a subset of
WS patients do not show mutations at the WRN locus (atypical WS),
but show heterozygous amino acid substitutions in the heptad repeat
region of lamin A [20–22].
Hutchinson Gilford progeria syndrome (HGPS, OMIM
176670) is a rare sporadic disorder with an incidence of 1 per
4–8 million live births, consisting of a premature aging phenotype
with rapid growth deceleration in childhood [18]. Appearance at
birth and birth weight are usually normal, but growth is typically
slowed by the age of one year [23]. The phenotypic appearance
consists of the following: short stature, sculpted nose, alopecia,
prominent scalp veins, loss of subcutaneous fat, and dystrophic
nails. In addition, HGPS patients show skeletal abnormalities that
may reflect deficient osteogenesis, principally in the extremities,
mandibular and cranial dysplasia with disorganized growth,
Academic Editor: Alfred Lewin, University of Florida, United States of America
Received October 5, 2007; Accepted November 10, 2007; Published December 5,
2007
This is an open-access article distributed under the terms of the Creative
Commons Public Domain declaration which stipulates that, once placed in the
public domain, this work may be freely reproduced, distributed, transmitted,
modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: This work was supported by The Progeria Research Foundation, The
Irving Foundation, and NIH Grants K01AR048594 and RO1AG025302 (to KD), NCI
R01CA114010 (to DMO), and from the intramural program of the National Human
Genome Research Institute (to FSC).
Competing Interests: The authors have declared that no competing interests
exist.
* To whom correspondence should be addressed. E-mail: kd206@columbia.edu
PLoS ONE | www.plosone.org 1 December 2007 | Issue 12 | e1269deformations in dentition and severe osteolysis [24] [25]. The
common causes of death in HGPS subjects during the second
decade of life are chronic conditions most common in elderly
people, especially coronary artery disease and stroke due to
widespread arteriosclerosis [26].
Nearly 90% of the subjects affected with HGPS carry a de novo
G608G (GGC.GGT) mutation within exon 11 of LMNA,
[22,27,28]. This single nucleotide change activates a cryptic splice
donor site, which results in a deletion of the 39 terminal 150
nucleotides of exon 11 of the mRNA, causing a 50 amino acid
internal truncation near the carboxyl-terminus of prelamin A [28].
The truncated lamin A, referred to as progerin, lacks amino acids
607 to 656 of prelamin A but retains the CAAX box [22,27,28].
Because the endoproteolytic cleavage site for ZMPSTE24 is lost in
the mutant protein, progerin remains permanently farnesylated
causing its tight association with the nuclear envelope and
producing numerous nuclear envelope abnormalities [29,30]. This
modification also appears to affect the dynamic state of progerin
within the lamina [31,32].
Cells derived from HGPS individuals and subjects with
pathologies resembling HGPS, such as atypical progeria Werner
Syndrome (WS), Restrictive Dermopathy (RD), and Mandibular
Dysplasia (MAD), appear to share a common feature: accumula-
tion of prelamin A, either as full-length prelamin A protein or
various truncated forms of prelamin A [14]. In all of these diseases,
the prelamin A or mutant prelamin A remains farnesylated and
accumulates within the nuclear compartment as cellular genera-
tion increases [29,30,33]. The persistence of the farnesylated form
appears to be the key element responsible for severe nuclear
abnormalities and defects in heterochromatin organization,
mitosis, DNA replication, transcription and repair [34–37].
Recently, rare fibroblasts cultured from elderly individuals were
found to exhibit nuclear phenotypes identical to those of HGPS
cells [38]. Intriguingly, while those cells expressed progerin mRNA
transcripts at barely detectable levels [38], long-term cultures
contained a few abnormal nuclei that were clearly positive with
anti-progerinspecificantibody[39].Theseobservationsindicatethat
progerin is also expressed in normal cells. Presumably, the cryptic
splice donor site in exon 11 of LMNA is activated by the HGPS
mutation, but the normal sequence is able to function in a similar
fashion under some circumstances, at least in long-term culture.
To further address the biological relevance of progerin
expression in unaffected individuals and its relationship to normal
aging, we followed the spatiotemporal expression pattern of
progerin in human skin at all ages. Herein, we provide new
evidence indicating that progerin is expressed and accumulates in
vivo during normal aging.
RESULTS
In vivo detection of progerin in unaffected
individuals
Using the human skin as our model system, we investigated
whether progerin is expressed in the skin of unaffected individuals.
150 skin biopsies from newborn foreskins and from unaffected
individuals, including equal numbers of females and males ranging
in age from 22 to 97 years were collected from the Dermatology
Clinic at Columbia University. The biopsies originated from
different body sites (Table 1). Using a one-step reverse transcrip-
tion polymerase chain reaction (RT-PCR), we screened total RNA
preparations isolated from skin biopsies. Primers in exon 9 and
exon 12, described previously [38], primarily amplified wild type
lamin A; however, a minor fragment similar in size to the HGPS
transcript was detected in 50 biopsies, examples of which are
shown in Figure 1A. Strikingly, the levels of amplified short
product remained low in all samples and no age-related differences
were observed. Sequencing of the short cDNA product derived
from RNA preparation of a 93 year-old donor was found to be
identical to the progerin cDNA sequence (Fig. 1B), demonstrating
that the progerin transcript, previously identified as an aberrant
lamin A product in HGPS, might constitute a true physiological
Figure 1. Progerin expression in human skin. A, RT-PCR analysis of HGPS cells and human skin biopsies of indicated age, primers amplifying wild-
type and progerin transcripts. B, Direct sequencing of a short portion within exon 11 of wild type lamin A (LMNA), and progerin transcripts from HGPS
and 93-year-old subjects. C, Western blot analysis of protein extracted from skin biopsies of indicated age with anti-progerin 972S9, anti-lamin A/C
and anti-actin antibodies.
doi:10.1371/journal.pone.0001269.g001





Newborn Foreskin 8 M
22 to 46 Breast 6 F
30 to 55 Face (cheek, forehead, scalp, ear, nose) Leg 8 F/10 M
56 to 70 Face (temple, cheek, forehead, scalp, ear, nose) 17 F/10 M
56 to 70 Neck, chest, Leg, back, hand 5 F/6 M
71 to 97 Face (temple, cheek, forehead, scalp, ear, nose) 26 F/33 M
71 to 97 Neck, chest, arm, Leg, back, hand 10 F/11M
Classification of the skin biopsies originating from different body sites of
unaffected individuals and collected at the Dermatology Department in
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slightly higher than the progerin product was detected in all skin
samples and was identified as the delta 10 isoform of lamin A [40].
The ubiquitous presence of a low level of progerin mRNA in
human skin also suggested that the protein, if present, would be
expressed at very low levels. We previously generated a rabbit
polyclonal antibody specific to lamin A G608G (progerin) [30]. This
previous polyclonal anti-progerin did not detect progerin in normal
tissue, and to rule out the possibility of the antibody being of low
affinity or that the recognized epitope might be masked, we
generated a rabbit monoclonal antibody using the same peptide as
antigen as described in Materials and Methods [30]. Three rabbits
were immunized. The serum of rabbit 972 specifically recognized
progerinproteinand gavenosignal withA-type laminincluding pre-
lamin A (data not shown). Spleen derived lymphocytes isolated from
rabbit 972 were used to generate hybridomas (Epitomics, Inc.;
Burlingame, CA, USA). One clone, 972S9, was selected based on its
specificreactionforprogerinandwasusedinthisstudy.Wescreened
40 skin biopsies of different ages for progerin expression by Western
blot analysis, and as indicated in a representative blot, a small
amount of progerin protein was present inskinsamples derived from
elderly individuals (Fig. 1C). Progerin was not detected in protein
extracts derived from young adult skin under our experimental
conditions, but low levels of expression were clearly detected in
samples derived from old skin and appeared to increase slightly with
the increasing chronological age of the donor (Fig. 1C).
Normal fibroblasts overexpressing progerin
recapitulate HGPS cellular phenotype
We established primary fibroblast cultures from skin biopsies of
normal individuals at different ages (Table 1). Primary fibroblast
cultures were made using two different methods either by explant
outgrowth or by enzymatic dissociation of the dermis [41]. Indirect
immunofluorescenceanalyseswereperformedwiththeanti-progerin
monoclonal antibody on fibroblast cultures at early population
doublings (PPDs). HGPS cultures below 25 PPDs showed that 27%
of nuclei were progerin-positive. In primary fibroblast cultures from
unaffected individuals, a few nuclei showed a positive staining
(Fig. 2A). Independently of the method used for their establishment,
cultures derived from young subjects (22 to 30 years) showed less
than 0.01% progerin-positive staining, while cultures derived from
elderly subjects exhibited an average of 0.3% to 0.8% progerin-
positive nuclei at early PPDs. Progerin-positive cells from normal
individuals showed nuclear abnormalities similar to those observed
in HGPS fibroblasts (Fig. 2A). Nuclear blebs, nuclear envelope
invaginations, binucleated cells and large nuclei, reminiscent of
abnormal cell cycle exit, were observed in all cultures derived from
elderly individuals, as was recently reported [39].
When fibroblast cultures were serially passaged to approach the
end of their lifespan, HGADFN 127 cells (HGPS) ceased to grow
when they reached approximately 40 to 45 PPDs under our
culture conditions. Indirect immunofluorescence analyses with
anti-progerin rabbit mAb 972S9 of HGPS cultures showed an
Figure 2. Progerin expression in primary dermal fibroblast cultures. A, Immunofluorescence microscopy on primary dermal fibroblasts from an
HGPS subject and unaffected individuals of indicated ages with rabbit monoclonal anti-progerin antibody. B, Immunofluoresence detection of
progerin in HGADFN 127 (HGPS individual) and DR118 (86-year-old individual) at late PPDs. C, Western blot analysis of nuclear protein extracts
derived from fibroblast cultures HGADFN 127 (HGPS) at PPD 20 and DR118 (86-year-old female) at PPD 15 and 30, respectively, were
immunoprecipitated with anti-progerin mAb 972S9 and the corresponding Western blot was probed with the same antibody.
doi:10.1371/journal.pone.0001269.g002
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towards late PPDs (above 35) nearly 90% of the cells were
progerin-positive (Fig 2 B). When similarly studies were performed
with normal fibroblast cultures, we noticed that the number of
cells positively labelled with anti-progerin Ab increased slightly
with the cellular-age in vitro. As exemplified, fibroblast culture
DR118 established from an 86 year-old female was monitored by
indirect immunofluorescence with anti-progerin mAb and exhib-
ited an average of 0.4% of progerin-positive cells in young cultures.
That average increased to 0.8% in late cultures (PPDs 30 to 35).
Western blot analysis of total protein extracts isolated from primary
fibroblast cultures derived from adult and elderly individuals
exhibited no progerin signal when probed with anti-progerin mAb,
while progerin was readily detected in total HGPS cellular extracts
at early PPDs (data not shown). Previously, we reported that
progerin accumulates in HGPS fibroblasts in a cellular-age-
dependent manner [30]. To verify further whether normal
fibroblasts could accumulate progerin in a similar fashion to the
HGPS counterpart, we performed immunoprecipitation assays
with anti-progerin mAb using nuclear extract preparation.
Immunoprecipitation of progerin was performed on isolated nuclei
preparation from an average of 6610
6 of normal cells from elderly
individuals at early and late PPDs (Fig. 2C). Western blot analyses
of immunoprecipitated materials were probed again with anti-
progerin mAb. Asindicated in Figure 2C, a low amount of progerin
could be detected at late PPDs ina representative fibroblast culture,
DR118 that was established from an 86 year-old female (Fig. 2C).
Collectively, these results indicate that low levels of progerin
protein are present in skin derived from elderly individuals as well as
in primary dermal fibroblast cultures established from this
population of subjects. Importantly, progerin appeared to accumu-
late in normal fibroblast cultures in a cellular-age-dependent
manner, but remained still relatively low when compared to the
amount of progerin accumulating in HGPS cultures [29,30].
In vivo profiling of progerin protein on skin biopsies
derived from HGPS and unaffected individuals using
an anti-progerin monoclonal antibody
To gain insight into the functional impact of the progerin isoform,
we examined human skin biopsies to determine the cellular
distribution of progerin in vivo. In skin sections derived from
a 9 year-old subject with HGPS (HGADFN143), we previously
demonstrated that progerin was localized in vascular cell nuclei
and in nuclei throughout the dermis [30]. Using the monoclonal
anti-progerin Ab, we reanalyzed sections from the same HGPS
sample. Progerin was detected within dermal nuclei, blood vessels,
arrector pili muscle, and cells surrounding the sweat glands
(Fig. 3A). Furthermore, progerin was detected in keratinocyte
nuclei in the upper most layers of the epidermis and localized into
a thick rim like structure at the nuclear envelope. This distribution
indicates that a subset of terminally differentiated keratinocytes
accumulates progerin in HGPS (Fig. 3A).
Since low levels of progerin mRNA were detected in total skin
mRNA preparations at all ages (Fig. 1A) and low amounts of
protein were detected in elderly skin extracts (Fig. 1C), we
hypothesized that progerin would be present at low levels or in
only a few cells. We performed immunohistochemistry on sections
derived from newborn foreskins and sixty skin biopsies from
different body sites (Table 1) of 22 to 93-year-old subjects.
Representative patterns of progerin localization are shown in
Figures 3 and 4. Newborn foreskin exhibited no signal with anti-
progerin mAb, while all nuclei showed a positive signal with anti-
lamin A Ab (Fig. 3C, panel LMNA). We noted that the upper
dermis on serial foreskin sections was highly vascularized;
numerous vascular loops were labelled with anti-a smooth muscle
actin Ab (aSMA) (Fig. 3B). Screening of five foreskin biopsies
detected no progerin in any skin compartment. Breast skin sections
from a 22-year-old female showed a few progerin-positive nuclei
close to the basement membrane and in the papillary dermis
(Fig. 3C). Breast skin sections from a 46-year-old woman exhibited
a greater number of progerin-positive nuclei dispersed throughout
the papillary dermis (Fig. 3C).
Sections from the forehead of a 69-year-old male, showed
progerin-positive nuclei mostly in the upper dermis (Fig. 4A). Skin
sections from the forehead of a 93-year-old female exhibited a high
density of progerin-positive nuclei in the upper and lower dermis
(Fig. 4B). A similar pattern of progerin distribution was detected in
skin sections from different body sites (Fig. 4C) including the hand
(60 years), leg (85 years) and scalp (90 years). Progerin was detected
as strong nuclear rim staining in fibroblasts located in the upper,
middleanddeepdermalcompartmentsinelderly individuals (Fig. 4B,
and 4C), while in young individuals, a few fibroblasts accumulating
progerin were localized in the papillary dermis close to the basement
membrane. With increasing age, the number of positive cells
increased in the upper dermis and progressively extended more
deeply, creating a gradient of progerin-positive fibroblasts from the
basement membrane to the reticular dermis. Skin derived from both
s u n - e x p o s e da r e a sa n dn o n - e x p o s e da r e a ss h a r e das i m i l a rd i s t r i b u -
tion of progerin-positive fibroblasts (Fig. 3 and 4).
Progerin was detected in a subset of terminally
differentiated keratinocytes in some skin biopsies
derived from elderly individuals
In the vast majority of unaffected skin biopsies tested herein,
progerin was not detected in the epidermis, as shown in Figure 3 to
4. However, in some skin biopsies derived from 70 to 95 year-old
subjects, a positive progerin signal was detected within the
epidermis. Representative examples of skin sections exhibiting
a progerin-positive signal in the epidermis are shown in Figure 5.
When progerin was detected in elderly epidermis, only a few
keratinocytes per section were positively labelled with anti-
progerin mAb in the uppermost layers of the epidermis and the
signal was never as bright as the one harbored by dermal
fibroblasts (Fig. 5). Skin sections from 76- and 95-year-old females
showed the highest number of positively labelled keratinocytes in
the granular layer of the epidermis (Fig. 5). However, the progerin-
positive keratinocytes were not uniformly distributed throughout
the entire length of the epidermis on the sections but rather were
localized within a small area. In most elderly skin sections, only
one to three keratinocytes were sporadically observed in the upper
most layer of the epidermis, as shown on an 86 year-old male skin
section (Fig. 5). In these terminally differentiated cells, progerin
signal was localized into a rim-like structure at the nuclear
periphery (Fig. 5). Overall, the progerin signal was weak compared
to the strong signal obtained in dermal fibroblasts.
These results indicate that progerin accumulates in terminally
differentiated keratinocytes that are localized within the layers
closer to the skin surface. Moreover, the progerin-positive
keratinocytes exhibited a thick nuclear rim staining, again
reminiscent of staining observed in progerin-positive keratinocytes
from HGPS skin sections (Fig. 3A). Since only very few
keratinocytes from the upper epidermis were labelled with anti-
progerin antibody, we could not rule out the possibility of epitope
masking which is common in lamin detection. We used different
fixation methods in combination with different permeabilization
procedures but the staining remained unchanged (data not shown).
Progerin Biomarker of Aging
PLoS ONE | www.plosone.org 4 December 2007 | Issue 12 | e1269The distribution and localization of the few progerin-positive
keratinocytes were consistent with observations of skin sections
derived from the patient with HGPS (Fig. 3A). As in HGPS
keratinocytes, the normal keratinocytes were terminally differen-
tiated as defined by their location in the uppermost layer of the
granular layer [42]. In addition, those progerin positive-keratino-
cytes exhibited identical rim-like staining at the nuclear envelope
periphery. While a progerin-positive signal was sporadically
detected in keratinocytes from the interfollicular dermis, no signal
was detected in the different epidermal appendages and
vasculature system regardless of body site or age of the donor
sample under our experimental conditions.
DISCUSSION
These data show for the first time that sporadic use of the cryptic
splice site in exon 11 of LMNA occurs in vivo in normal cells,
however that site is much more active in HGPS cells carrying the
LMNA G608G mutation. Progerin mRNA transcripts were
detected at very low levels in all skin samples of unaffected
individuals and remained fairly constant at all ages (Fig. 1). A
similar observation was previously reported using fibroblast
cultures derived from healthy individuals [38].
While the progerin mRNA could be detected at uniform levels
by RT-PCR analysis in all tissue samples, the protein apparently
accumulated with age. Western blot analysis was capable of
Figure 3. In situ localization of progerin on human skin sections derived from a subject with HGPS and from unaffected individuals. A, HGPS skin
sections immunostained with anti-progerin (prog), anti-lamin A (LMNA) antibody, or anti-a smooth muscle actin antibody (aSMA) and counterstained
with a DNA stain (dapi). Morphologic entities are indicated: epidermis (ep), dermis (de), sweat glands (SG), capillary (c), arrector pili muscle (a), and
hair follicle (h). B, Newborn foreskin sections immunolabelled with anti-progerin or anti-aSMA antibody. C, Breast skin sections from 22- and 46-year-
old female subjects probed with anti-progerin and lamin A. The respective double or triple merged signals are indicated.
doi:10.1371/journal.pone.0001269.g003
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individuals (Fig. 1C), but the protein was below limit of detection
in young samples. In skin biopsies from young individuals,
progerin was either absent or present only at low levels, since it
was not detectable by indirect immunofluorescence (Fig. 3). With
advancing age, concomitant with alterations of the dermal
compartment (such as disorganized connective tissue), progerin
accumulated in skin cells but was restricted to specific cell types,
primarily dermal fibroblasts and terminally differentiated kerati-
nocytes. Thus, progerin-positive cells were not randomly distrib-
uted within the skin (Fig. 3 to 5). In the dermis, progerin-positive
fibroblasts appeared first at the basement membrane and their
number increased and spread throughout the dermis with age
(Fig. 3 and 4).
Dermal fibroblasts are the major cell type in the dermis and
represent a heterogeneous population of cells based on differences
in proliferation potential and extracellular matrix protein synthesis
[43]. Our findings indicate that the population of progerin-positive
fibroblasts might characterize a possible terminal differentiation
phenotype of dermal fibroblasts in vivo. In support of this
observation, our results indicate that progerin-positive cells are
not randomly distributed in the dermis, but appear in an age-
related fashion at the basement membrane and gradually spread
throughout the dermal compartment (Fig. 3 and 4). Moreover,
while a high number of progerin-positive cells were detected in
skin biopsies of older individuals, only a few of them were found in
the respectively derived fibroblast cultures (Fig. 2), suggesting that
the progerin-positive cells might have reached terminal growth
Figure 4. Progerin accumulation in human elderly skin biopsy sections. A, Forehead skin section from a 69-year-old individual probed with anti-
progerin antibody and counterstained with dapi. Bars correspond to 100 and 50 mm, respectively. B, Forehead skin section from a 93-year-old donor.
C, Skin sections from different body sites as indicated were probed with anti-progerin and anti- lamin A (LMNA) antibodies. Bar, 50 mm. Merged
images are indicated.
doi:10.1371/journal.pone.0001269.g004
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their number increased slightly in late passage cultures suggesting
that progerin accumulates in cells that have entered a stage of
terminal differentiation or senescence.
We and others have previously reported that progerin build-up in
HGPS cells occurs in a cellular-age-dependent manner [29,30].
Moreover, accumulation of progerin has a negative impact on cell
cycle progression and elicits reduced migration in HGPS fibroblasts
[30,39]. Altogether, these findings indicate that progerin-positive
fibroblasts in vivo might define a subpopulation of fibroblasts that
have reached terminal differentiation and/or senescence.
The epidermis is a self-renewing stratified epithelium mainly
composted of keratinocytes that undergo a complex and dynamic
program of terminal differentiation throughout life [44]. This
process starts when proliferating keratinocytes of the basal layer
move upward to the suprabasal layers and progressively acquire
the ability to express sequentially the specific gene products that
are required for differentiation [45]. Terminally differentiated
keratinocytes of the granular layer are in a transitional stage on
their way to forming the cornified layer of the epidermis [44]. This
transition is accompanied by the elimination of all organelles
including the nuclei and changes in cytoplasmic functions. These
cellular events allow the production of the outermost epidermal
layer, composed of the flattened, enucleated, dead cornified cells
(corneocytes) that ensure the skin barrier function [44]. Strikingly,
it is within this transitional epithelial layer that progerin appears
within a small subset of keratinocytes. These cells not only have
reached terminal differentiation but also are about to extrude their
nuclei and as such could be considered as having reached the end
of their lifespan. Such terminal differentiation and transitional
stages between nucleated and enucleated cells must imply not only
an important rearrangement of the nucleus but must also implicate
a large-scale genome reorganization designed to switch off gene
expression that is no longer required. Such remodelling of the
nuclear lamina composition and changes in heterochromatin
epigenetic marks to silence gene expression and overall chromatin
organization must synergistically and actively participate in the
settings of nuclear exclusion. We suggest that during this final stage
of terminal differentiation, the keratinocytes must have reached
the end of their lifespan in vivo and may be regarded as senescent
cells [46,47].
Replicative senescence is a permanent state of proliferation
arrest [48]. Terminal differentiation defines cells that permanently
exit the cell cycle in the course of acquiring functional
specialization. Both cellular stages share some common properties
including stable cell-cycle arrest, flattened and enlarged morphol-
ogy, increased cytoplasmic enzymatic vesicles, and changes in
chromatin condensation and in gene expression patterns [49,50].
Progerin is linked to the pathogenesis of HGPS and exerts
a toxic nuclear effect because it remains permanently farnesylated
[18]. Cells derived from subjects with HGPS exhibit dysmorphic
nuclei with significant changes in nuclear shape, including nuclear
envelope invaginations, thickening of the nuclear lamina, loss of
peripheral heterochromatin, and clustering of the nuclear pores
[29,30]. The changes in the lamina protein composition appear to
be responsible for the disruption and loss of peripheral chromatin
in HGPS cells, and has been linked to impaired epigenetic histone
markers and genomic instability [34].
Our findings further extend these previous studies by showing
the dynamic changes in the nuclear lamina composition with the
incorporation of an ‘‘age-associated’’ lamin isoform progerin
during the process of keratinocyte differentiation in vivo.W e
postulate that, analogous to the process that occurs in HGPS cells,
the build-up of progerin in the nuclear lamina in normal cells
contributes to the delocalisation of heterochromatin clusters away
from the nuclear periphery, thereby contributing to the large scale-
genome decondensation to allow genomic reorganization. This
reorganization is requisite to ensure terminal differentiation and/or
senescence. Finally, the association between progerin build-up to
terminal differentiation and/or senescence in normal cells suggests
that in the context of HGPS cells, progerin accumulation could
trigger abnormal differentiation and early senescence which would
prematurely deplete the pool of mitotic cells with renewal potency
from tissue and cause the clinical sequelae that characterize old age.
As progerin appears to be a cellular aging biomarker for dermal
fibroblasts and keratinocytes of normal individuals in vivo, we are
drawn to the conclusion that HGPS may indeed be a useful model
in which to learn more about normal aging. Therapeutic strategies
already tested on HGPS cells, such as farnesyltransferase
inhibitors, might even be useful in preventing normal aging and
possibly slowing progression of other age-related pathologies.
MATERIALS AND METHODS
Production and characterization of a rabbit
monoclonal anti-lamin A G608G antibody
The lamin A G608G amino acid sequence reading frame was
determined previously [27,51]. To generate a specific anti-Lamin
A G608G antibody, we chose a short peptide overlapping the
region where the 50 amino acid internal deletion occurred in
lamin A mutant G608G sequence as described previously [30].
Three rabbits were immunized with the peptide using the standard
protocol performed by Covance ImmunoTechnologies (Denver,
PA, USA). Preimmune and immune sera were characterized by
Western blot analysis and indirect immunofluorescence on HGPS
and control fibroblast cells. The serum of rabbit 972 specifically
recognized progerin protein and gave no signal with A-type lamin
Figure 5. Progerin detection in a subset of terminally differentiated
keratinocytes. Left panels correspond to anti-progerin monoclonal
antibody staining of skin sections derived from individuals of indicated
age. Right panels correspond to the merged signal of dapi and progerin
signals. Square indicates the zoomed in region of the epidermis. ep
denotes epidermis, and de the dermis.
doi:10.1371/journal.pone.0001269.g005
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Epitomics, Inc (Burlingame, CA, USA). Lymphocytes were
isolated from the spleen and fusion was performed according to
Epitomics’ standard protocol. Positive hybridomas were selected
and the supernatants of the primary clones and subsequent
subclones were screened by Western blot and indirect immuno-
fluorescence analysis using control and HGPS dermal fibroblasts
treated or untreated with FTI as described previously [30]. One
clone, 972S9, was selected based on its specific reaction for
progerin and was used in this study.
Human skin biopsy sections and primary dermal
fibroblast cultures
Normal skin biopsies and newborn foreskins were obtained from
the Dermatology Clinic in accordance with the health research
ethics board of Columbia University. The biopsies originated from
different body sites and were obtained from equal numbers of
males and females. The sex, age and body site of each donor was
recorded (Table 1). Skin biopsies were embedded in Optimum
Cooling Temperature medium (O. C. T.) and cryopreserved for
tissue sectioning. Serial 6 mm frozen skin sections were prepared
and stored at 280uC. In addition, small pieces were snap frozen in
liquid nitrogen at the time of their collection for mRNA and
protein extractions. Primary cultures of dermal fibroblasts were
established using explant culture or enzymatic digestion of the skin
as described previously [41].
Briefly, skin tissue was rinsed in PBS and incubated overnight in
a Dispase II solution at 4uC. The epidermis and dermis were
mechanically separated and primary HDF cultures were estab-
lished using explants or enzymatic digestion methods of the
dermis. For explant culture, the dermal portion of the skin was
washed in PBS supplemented with penicillin and streptomycin cut
into small pieces, and spread onto a culture dish. Culture medium,
DMEM supplemented with 15% fetal bovine serum, was added.
Fibroblast outgrowth started at day 3 to 7; the skin pieces were
removed after a week and cultures were grown to 70% confluence.
For HDF cultures established by enzymatic dissociation of the skin,
dermal pieces were transferred to a solution of Collagenase I
(Worthington Biochemical) at 200 units/mL of 16PBS including
0.3 mM CaCl2. The pieces were kept at 37uC shaking for 1 to
4 hours until they were digested. The solution with the dermal
fragments was then diluted 5-fold with complete DMEM medium
(15% FBS, 1% penicillin-streptomycin, 1% L-glutamine), passed
over a 70 mm cell strainer (BD Falcon) and centrifuged. The cell
pellet was resuspended in complete medium and the cells were
plated, grown to 70–80% confluence and cryopreserved at 280uC.
HGPS skin biopsy and dermal fibroblast cells
Dermal fibroblasts derived from HGPS patients carrying the
LMNA mutation G608G (HGADFN001, HGADFN003, and
HGADFN127) were grown as described previously [30]. The
Progeria Research Foundation kindly provided the HGPS cells and
frozen skin sections derived from a skin biopsy of a 9 year-old donor
with HGPS carrying LMNA G608G mutation (HGADFN143).
One step-Reverse Transcription/Polymerase Chain
Reaction (RT-PCR)
Total RNA was extracted from skin biopsy pieces using an RNA
extraction kit as per the manufacturer (QIAGEN). 1 mg of RNA
from each sample was submitted to one step RT-PCR (OneStep
RT-PCR, QIAGEN) using primers located in exon 9 and 12 of
lamin A (forward primer: 59 GGCTGCGGGAACAGC 39, and
reverse primer: 59 CTGGCAGGTCCC 39) described previously
[38], together with primers located in human b actin isoform
(Forward: CCCAGCACAATGAAGATCAA and reverse GTG-
TAACGCAACTAAGTCAT) as internal control. 50 ml reactions
were submitted to reverse transcriptase for 30 minutes at 50uC,
followed by PCR activation step at 95uC for 15 minutes. PCR
conditions were 35 cycles, each cycle consisting of 30-sec
denaturation at 94uC, 30-sec annealing at 55uC, and 30-sec
polymerization at 72uC. 15 ml of the reaction was analysed on 2%
agarose gel and stained with ethidium bromide.
Indirect immunofluorescence
Primary cultures of dermal fibroblasts from patients and controls
were processed for indirect immunofluorescence as described
previously [51]. Mouse anti-lamin A Jol4 (Serotec) or clone 133A2
(abcam), anti-lamin A/C 131C3 (abcam), and anti-human a smooth
muscle actin, clone 1A4 (DakoCytomation) were purchased. The
secondary antibodies were affinity purified Alexa Fluor 488 goat or
donkey IgG antibodies (Molecular Probes) and Cy3-conjugated IgG
antibodies (Jackson ImmunoResearch laboratories). All samples
were also counterstained with DAPI (Sigma-Aldrich).
Immunohistochemistry was performed on 6 mm frozen sections
fixed by methanol/acetone (1V/1V) at 220uC for 10 minutes and
washed in PBS, then blocked in PBS buffer containing 3% BSA,
10% normal goat serum and 0.3% Triton X-100 for 30 minutes
and 1 hour in the same buffer without Triton X-100. Slides were
incubated with the monoclonal anti-progerin antibody for 1 hour.
After 6 washes in blocking buffer, slides were incubated with
donkey anti-rabbit affinity purified Cy3-conjugated IgG anti-
bodies. Slides were washed in blocking buffer and in PBS, then
mounted with Vectashield mounting medium (Vector Inc.)
Western blot analysis
Skin tissues were extracted in cytoskeleton buffer (CSK) (100 mM
NaCl, 300 mM sucrose, 10 mM PIPES (pH 6.8), 3 mM MgCl2,
0.5% triton X-100) and protease inhibitors (Roche) for 15 minutes
on ice. Skin pieces were minced and homogenized with PowerGen
125 (Fisher Scientific) in CSK buffer. The insoluble material was
digested in PBS buffer containing 100 mg/ml of DNAse I and
100 mg/ml of RNAse A (Sigma) for 20 minutes at 20uC; after
centrifugation the remaining pellet was resuspended in Laemmli
sample buffer (BioRad) and boiled 5 minutes at 95uC. Equal
amounts of extracts were loaded in parallel on a 7.5% poly-
acrylamide gel. After separation by electrophoresis, proteins were
transferred tonitrocellulosemembranesandincubatedwithblocking
buffer as described previously [30]. Membranes were incubated with
primary antibodies (Ab 972S9, anti-lamin A/C kindly provided by
Dr. N. Chaudhary, anti-actin Ab (Sigma)), washed, and then
incubated with the corresponding secondary antibody coupled to
horseradish peroxidase (Jackson ImmunoResearch Laboratories).
Proteins were visualized using the enhanced chemiluminescence
detection system (Amersham Pharmacia Biotech).
Western blot analysis of progerin expression in normal
fibroblast cultures established from an 86-year-old female was
performed after immunoprecipitation of nuclei extract prepared
from early (PPD 15) and late population doublings (between 30 to
35 PPDs). Nuclei were isolated from normal cell pellets, containing
an average of 6610
6 cells, and from HGPS cell pellets, containing
2610
6 cells at early PPDs (below 25), in buffer A (10 mM HEPES
(pH7.9), 1.5 mM MgCl2, 10 mM KCL) supplemented with
protease inhibitor cocktail tablet (Roche Applied Science). After
10 minutes incubation on ice, the preparation was dounce
homogenized by 25 strokes followed by 10 minutes centrifugation
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supplemented with protease inhibitors and were briefly sonicated
on ice and centrifuged at 4uC. Extracts were incubated with 10 mg
of purified 972S9 IgG (anti-progerin rabbit monoclonal) for
4 hours at 4uC; 30 ml of protein A sepharose, equilibrated in RIPA
buffer, was added and the extracts were incubated for another
hour at 4uC. After four washes in RIPA buffer and two washes in
PBS, the IP pellets were resuspended in 50 ml Laemmli sample
buffer (BioRad), separated on SDS-PAGE gels, and transferred
onto nitrocellulose. Westerns were probed with anti-progerin
rabbit mAb 972S9 and further processed as described above.
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